- April 21, 2020– In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit Viral Replication of SARS-CoV-2 – – Live…
- April 17, 2020NEW YORK, April 17, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the…
- March 15, 2020– Top-Line Data from Phase 2 EMPhASIS Trial in Relapsing-Remitting Multiple Sclerosis Expected in Third Quarter 2020 – – Cash of…
- February 11, 2020NEW YORK, February 11, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the…
- January 8, 2020Phase 1 Clinical Studies to begin in First Half of 2020 NEW YORK, January 8, 2020 – Immunic, Inc. (Nasdaq: IMUX), a…
